Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: A case for a Fixed Dose Combination (FDC) for the treatment of tuberculusosis

Central African Journal of Medicine

Volumn 45, Issue 6, 1999, Pages 141-142

  Nyazema, N Z ^a   Rabvukwa, P ^a   Gumbo, J ^a   Ndudzo, P ^a   Chitemerere, C ^b  

^a UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

^b Varichem (Pvt) Ltd   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; SINGLE BLIND PROCEDURE; TIME; TUBERCULOSIS;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; MALE; METABOLIC CLEARANCE RATE; RIFAMPIN; SINGLE-BLIND METHOD; TIME FACTORS; TUBERCULOSIS;

EID: 0033138583     PISSN: 00089176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. The promise and the reality of fixed dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the Tuberculosis Programme of the World Health Organisation. Tuber Lung Dis 1994;75:180-7.
2. International Union Against Tuberculosis and Lung Diseases. Anti-tuberculosis regimens of chemotherapy. Recommendations from the committee on the Treatment of the IUATLD. Bull Int Union Tuberc Lung Dis 1998;63:60-4.
3. Editorial. Quality control and essential drugs. Lancet 1997;555:601.
4. Fox W. Combinations and the bioavailability of Rifampicin. Tubercle 1990;71:241-5.
5. Henwood SQ, de Villies MM, Liebenberg W, Dotter AP, Dekker TG. Rifampicin polymorphs found among raw materials available in South Africa. Abstr P 14. 31 Annual Conference/workshop South African Pharmacology Society 1997.
6. Ministry of Health and Child Welfare. Practical guidelines on the treatment of TB in the private health sector. Ministry of Health and Child Welfare, Zimbabwe. Department of Epidemiology and Disease Control, 1999.
7. Furesz S, Scotti R, Pallanza R, Mapelli E. Rifampicin: - a new rifampicin. III. Absorption, distribution and elimination in man. Arzneimilteel-Forsch 1967;17:534-7.
8. Prober C. Rifampicin In: Principles of medical pharmacology. Roschlan W, editor. Inc. New York:Oxford University Press, 1985:660-1.
9. WHO. Certification scheme on the quality of pharmaceutical products moving in international commerce. WHA 28-65B. Geneva, 1993.